Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 13/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.50 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.50 |
| ▸ | HTR3A | P46098 | 1/20 | 0.50 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.48 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18608877 | 0.89 | NOTUM (0.55) | NOTUMCYP1A2CYP2C9CHRNB2CYP2B6 | |
| SCHEMBL9945328 | 0.83 | ALDH1A1 (0.57) | NOTUMCYP1A2CYP2C9CHRNB2CYP2B6 | |
| SCHEMBL15150640 | 0.80 | NOTUM (0.53) | NOTUMCYP1A2CYP2C9CHRNB2CYP2B6 | |
| SCHEMBL17666298 | 0.80 | NOTUM (0.56) | NOTUMCYP1A2CYP2C9CHRNB2CYP2B6 | |
| SCHEMBL18586211 | 0.79 | NOTUM (0.55) | NOTUMCYP1A2CYP2C9CHRNB2CYP2B6 | |
| SCHEMBL17007151 | 0.79 | NOTUM (0.51) | NOTUMCYP1A2CYP2C9CHRNB2CYP2B6 | |
| SCHEMBL10104439 | 0.77 | ALDH1A1 (0.43) | NOTUMHCRTR1ALDH1A1KDM4EPKM | |
| SCHEMBL15594057 | 0.77 | NOTUM (0.53) | NOTUMCYP1A2CYP2C9CHRNB2CYP2B6 | |
| SCHEMBL2627308 | 0.77 | ALDH1A1 (0.49) | NOTUMCYP1A2CYP2C9CHRNB2CYP2B6 | |
| SCHEMBL12391461 | 0.76 | NOTUM (0.57) | NOTUMCYP1A2CYP2C9CHRNB2CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8778929-B2 | Substituted heteroaryl inhibitors of B-RAF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-15 | — | — | US | disclosed |
| US-8653087-B2 | Pyrido [5, 4-D] pyrimidines as cell proliferation inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-18 | — | — | US | disclosed |
| US-20120094975-A1 | PYRIDO [5, 4-D] PYRIMIDINES AS CELL PROLIFERATION INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-19 | — | — | US | disclosed |
| US-20110312939-A1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| US-8003657-B2 | Heterocyclic substituted bisarylurea derivatives | MERCK PATENT GMBH (DE) | 2011-08-23 | — | — | US | disclosed |
| US-8003657-B2 | Heterocyclic substituted bisarylurea derivatives | MERCK PATENT GMBH (DE) | 2011-08-23 | — | — | US | disclosed |
| US-20090253688-A1 | Semicarbazide derivatives as kinase inhibitors | MERCK PATENT GMBH (DE) | 2009-10-08 | — | — | US | disclosed |
| US-20090253688-A1 | Semicarbazide derivatives as kinase inhibitors | MERCK PATENT GMBH (DE) | 2009-10-08 | — | — | US | disclosed |
| US-20090215799-A1 | HETEROCYCLIC SUBSTITUTED BISARYLUREA DERIVATIVES | MERCK PATENT GMBH | 2009-08-27 | — | — | US | disclosed |
| US-20090215799-A1 | HETEROCYCLIC SUBSTITUTED BISARYLUREA DERIVATIVES | MERCK PATENT GMBH | 2009-08-27 | — | — | US | disclosed |
| US-20090124633-A1 | N-OXIDES OF HETEROCYCLIC SUBSTITUTED BISARYLUREAS FOR TREATING KINASE-MEDIATED DISEASES | MERCK PATENT GESELLSCHAFT (DE) | 2009-05-14 | — | — | US | disclosed |
| US-20090124633-A1 | N-OXIDES OF HETEROCYCLIC SUBSTITUTED BISARYLUREAS FOR TREATING KINASE-MEDIATED DISEASES | MERCK PATENT GESELLSCHAFT (DE) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124633-A1 | N-OXIDES OF HETEROCYCLIC SUBSTITUTED BISARYLUREAS FOR TREATING KINASE-MEDIATED DISEASES | ABL1, NME2, MAP3K1 | NOTUM 1938/4885CYP1A2 462/4885CYP2C9 518/4885 |
| US-20110312939-A1 | NEW CHEMICAL COMPOUNDS | CCNA1, CCNT1, MKI67 | NOTUM 4461/4885CYP1A2 174/4885CYP2C9 1081/4885 |
| US-20090215799-A1 | HETEROCYCLIC SUBSTITUTED BISARYLUREA DERIVATIVES | ABL1, BTK, PRKACA | NOTUM 1328/4885CYP1A2 280/4885CYP2C9 168/4885 |
| US-20090253688-A1 | Semicarbazide derivatives as kinase inhibitors | MAP3K1, MAP3K6, MAP3K2 | NOTUM 2459/4885CYP1A2 2621/4885CYP2C9 1834/4885 |
| US-20120094975-A1 | PYRIDO [5, 4-D] PYRIMIDINES AS CELL PROLIFERATION INHIBITORS | CCNT1, CCNA1, CCND1 | NOTUM 4803/4885CYP1A2 604/4885CYP2C9 832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.